Although the FDA's 27 new approvals are down from the 15-year high of 2012, the newcomers pack powerful commercial potential.
Change history
07 February 2014
The titles of David Greber and Ulrik Schulze have been updated online.
Rights and permissions
About this article
Cite this article
Mullard, A. 2013 FDA drug approvals. Nat Rev Drug Discov 13, 85–89 (2014). https://doi.org/10.1038/nrd4239
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4239
- Springer Nature Limited
This article is cited by
-
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Molecular and Cellular Biochemistry (2023)
-
Drug repurposing for antimicrobial discovery
Nature Microbiology (2019)
-
ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database
Journal of Cheminformatics (2018)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward
Blood Cancer Journal (2016)